Published in World J Gastroenterol on August 07, 2013
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol (2014) 0.89
Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review. World J Gastroenterol (2016) 0.81
Genetic variants in the EPCAM gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma with portal vein tumor thrombus. PLoS One (2014) 0.80
Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma. PLoS One (2014) 0.76
S-1 for treatment of advanced hepatocellular carcinoma: a systematic review of the literature. Contemp Oncol (Pozn) (2017) 0.75
Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus. Medicine (Baltimore) (2016) 0.75
New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Clin Transl Hepatol (2017) 0.75
Complications in hepatic arterial infusion chemotherapy: retrospective comparison of catheter tip placement in the right/left hepatic artery vs. the gastroduodenal artery. Surg Today (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67
Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology (2006) 3.68
Pathology of hepatocellular carcinoma in Japan. 232 Consecutive cases autopsied in ten years. Cancer (1983) 3.28
Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol (2007) 3.14
Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology (2004) 2.91
[Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol (2009) 2.48
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer (2002) 2.13
Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer (2006) 1.87
A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol (2010) 1.77
Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology (2000) 1.64
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol (2012) 1.57
Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol (2007) 1.48
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer (2012) 1.45
Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev (1988) 1.25
Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology (1992) 1.24
Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period. Clin Mol Hepatol (2012) 1.14
Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer (2007) 1.11
A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol (2009) 1.06
Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J Clin Gastroenterol (2009) 1.01
Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases. J Gastroenterol Hepatol (2012) 0.97
Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol (2003) 0.96
Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol (2009) 0.96
Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. World J Gastroenterol (2012) 0.95
Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. Eur J Gastroenterol Hepatol (2012) 0.95
A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Korean J Hepatol (2010) 0.94
Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology (2011) 0.93
Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia Pac J Clin Oncol (2010) 0.92
Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? World J Gastroenterol (2012) 0.82
Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol (2012) 0.80
Neurogenic tumors in the abdomen: tumor types and imaging characteristics. Radiographics (2003) 3.90
A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol (2012) 2.43
Percutaneous management of postoperative duodenal stump leakage with foley catheter. Cardiovasc Intervent Radiol (2013) 2.17
A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology (2006) 2.05
Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms. J Gastroenterol Hepatol (2006) 2.04
Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer (2010) 1.92
The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med (2008) 1.88
Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study. J Med Virol (2013) 1.86
The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist (2010) 1.84
Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol (2004) 1.82
Early gastric cancer associated with gastritis cystica polyposa in the unoperated stomach treated by endoscopic submucosal dissection. Gastrointest Endosc (2009) 1.67
Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma. Antivir Ther (2011) 1.65
Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol (2012) 1.63
Helical tomotherapy for simultaneous multitarget radiotherapy for pulmonary metastasis. Int J Radiat Oncol Biol Phys (2009) 1.63
Integrative analysis of multiple gene expression profiles applied to liver cancer study. FEBS Lett (2004) 1.63
Review of failed CT phantom image evaluations in 2005 and 2006 by the CT accreditation program of the Korean Institute for Accreditation of Medical Image. Korean J Radiol (2008) 1.60
Transcatheter arterial embolization for endoscopically unmanageable non-variceal upper gastrointestinal bleeding. Scand J Gastroenterol (2015) 1.52
Sustained low hepatitis B viral load predicts good outcome after curative resection in patients with hepatocellular carcinoma. J Gastroenterol Hepatol (2010) 1.51
Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology (2011) 1.48
Early CT findings of tomotherapy-induced radiation pneumonitis after treatment of lung malignancy. AJR Am J Roentgenol (2009) 1.48
Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL. Urology (2010) 1.48
Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol (2012) 1.47
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut (2013) 1.46
Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res (2008) 1.45
Can "healthy" normal alanine aminotransferase levels identify the metabolically obese phenotype? Findings from the Korea national health and nutrition examination survey 2008-2010. Dig Dis Sci (2014) 1.43
Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer (2008) 1.40
[In vitro culture of hepatitis C virus (HCV) using immortalized hepatocyte]. Korean J Gastroenterol (2008) 1.39
Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys (2010) 1.36
CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett (2011) 1.33
Prevalence and risk factors for erectile dysfunction in Korean men: results of an epidemiological study. J Sex Med (2007) 1.32
The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma. Cancer Res (2004) 1.30
Titanium dioxide nanoparticles trigger p53-mediated damage response in peripheral blood lymphocytes. Environ Mol Mutagen (2008) 1.30
A comparative study of methods of estimating kidney length in kidney transplantation donors. Nephrol Dial Transplant (2007) 1.27
Gene expression profiling of human HBV- and/or HCV-associated hepatocellular carcinoma cells using expressed sequence tags. Int J Oncol (2006) 1.26
Pharmacotherapy for erectile dysfunction. J Sex Med (2010) 1.24
HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-beta1. Exp Mol Med (2005) 1.20
The relationship between subjective and objective parameters in CT phantom image evaluation. Korean J Radiol (2009) 1.19
Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci (2005) 1.18
Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology (2006) 1.18
MR Imaging findings of hydrosalpinx: a comprehensive review. Radiographics (2009) 1.17
Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol (2011) 1.15
Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period. Clin Mol Hepatol (2012) 1.14
SOX4 overexpression regulates the p53-mediated apoptosis in hepatocellular carcinoma: clinical implication and functional analysis in vitro. Carcinogenesis (2010) 1.13
Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J Clin Virol (2011) 1.13
Additional sex comb-like (ASXL) proteins 1 and 2 play opposite roles in adipogenesis via reciprocal regulation of peroxisome proliferator-activated receptor {gamma}. J Biol Chem (2010) 1.12
Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res (2004) 1.12
A novel Wilms tumor 1 (WT1) target gene negatively regulates the WNT signaling pathway. J Biol Chem (2010) 1.09
Simultaneous multitarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases. Int J Radiat Oncol Biol Phys (2008) 1.09
Prevalence and correlates of erectile dysfunction (ED) and treatment seeking for ED in Asian Men: the Asian Men's Attitudes to Life Events and Sexuality (MALES) study. J Sex Med (2007) 1.09
SUMO-specific protease SUSP4 positively regulates p53 by promoting Mdm2 self-ubiquitination. Nat Cell Biol (2006) 1.06
A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol (2009) 1.06
A preliminary investigation of early smoking initiation and nicotine dependence in Korean adults. Drug Alcohol Depend (2004) 1.06
The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci (2005) 1.06
Silencing of 14-3-3ζ over-expression in hepatocellular carcinoma inhibits tumor growth and enhances chemosensitivity to cis-diammined dichloridoplatium. Cancer Lett (2011) 1.05
Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf (2012) 1.05
Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol (2004) 1.05
Electrospinning of chitin nanofibers: degradation behavior and cellular response to normal human keratinocytes and fibroblasts. Biomaterials (2006) 1.04
Epidemiology and risk factors for bacteremia in 144 consecutive living-donor liver transplant recipients. Yonsei Med J (2009) 1.04